The case for modernizing biodistribution reporting in nuclear medicine

Radiopharmaceutical dosimetry (RD) is an integral part of nuclear imaging and therapy, but current standards for documenting and reporting compound travel patterns inside the human body—biodistribution—in dosimetry-related studies do not exist. 

A March 30 Journal of Nuclear Medicine article argues all publication of RD estimates need to include the associated biodistribution characterizations used to create them.

“Biodistribution data is already collected in every dosimetry case, and its standard documentation may help us understand the value and limitations of our RD, identify errors, resolve discrepancies, and enable the reproducibility of results,” wrote corresponding author Adam Kesner, PhD, and assistant attending of nuclear imaging physics at Memorial Sloan Kettering Cancer Center, and colleagues.

In imaging, accurate and replicable dosimetry is critical because the tracer dose can vary widely across radiopharmaceuticals, and understanding individual risk is important to ensure optimal imaging and regulation compliance.

The pair of authors writes the biodistribution summary should provide accounting for “100 percent of the activity modeled in the presented osimetry calculations.”

This includes time-integrated activity coefficients for all patients involved in the study, including organ uptake, remainder-of-body uptake and assumed waste, according to Kesner et al. This information can be formatted as a table and included in the body, appendix or supplementary data portions of published articles, they add.

“Ultimately [RD documentation] may improve the current generally poor acceptance of dosimetry procedures by clinicians,” wrote Kesner et al. “We are now at an opportune time when changing our reporting practices is practical and can lay the groundwork for a more robust and dynamic field in the coming decades.”

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

HeartFlow kicked off TCT 2024 by sharing new research on the long-term impact of its FFRCT Analysis and Plaque Analysis software.

Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.

Trimed Popup
Trimed Popup